Forefront of developing new possibilities
through innovative technology

Platform Technology

  • Next-generation stem cell (ENCT)
  • Viral vector

Next-generation stem cell therapy

Next-generation stem cells with high yield and efficiency
Enhanced Neo Cell (ENCell)

Conventional Cell Therapy

ENCell

Low yield and high cost

Cost reduction through high-yield production technology

High variability in quality

Reduced variability, increased efficiency

Limited applications

cryopreserved formulations with uniform formats

ENCT technology enabled us to obtain a greater number of cells compared to conventional methods,
while maintaining consistent quality and reducing production time.
This resulted in a notable improvement in therapeutic efficacy by reducing stem cell senescence.

EN001 is a mid-stage stem cell therapy with a high yield and efficiency,
produced using ENCT, our proprietary core technology.

EN001 Summary of Features

  • Optimized Tissue Selection Technology : Wharton's Jelly-derived mesenchymal stem cells (WJ-MSC)
  • Simulated Wharton's Jelly Microenvironment Cultivation Method : Reduced cultivation period (1×10⁹ cells require over 20 days; reduced by more than 20 days compared to conventional methods)
  • Enhanced applicability through cryopreserved formulations
  • Targeted therapeutic efficacy for muscular diseases
    • Indications
    Charcot-Marie-Tooth
    disease 1A
    (CMT1A)    		 Duchenne Muscular Dystrophy (DMD) Sarcopenia
    STEM CELLs, 2021
    (IF 6.277)
    Featured article
    and 3 more articles    		 Molecular Therapy, 2016
    (IF 12.910)
    and 3 more articles    		 -